

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Stromatt Scott C</u>			2. Issuer Name and Ticker or Trading Symbol <u>Aptevo Therapeutics Inc. [APVO]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) <u>Chief Medical Officer and SVP</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>08/03/2016</u>			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
2401 4TH AVENUE, SUITE 1050			4. If Amendment, Date of Original Filed (Month/Day/Year) <u>08/05/2016</u>					
(Street) <u>SEATTLE WA 98121</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								2,244 ⁽¹⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Unit	(2)	08/03/2016		A		54,762		(3)	(3)	Common Stock	54,762	\$0	54,762	D	
Restricted Stock Unit	(2)	08/03/2016		A		78,123		(4)	(4)	Common Stock	78,123	\$0	234,322 ⁽⁵⁾	D	
Stock Option (right to buy) ⁽⁶⁾	(7)							(8)	(9)	Common Stock	202,880		202,880	D	

Explanation of Responses:

- This report has been amended to reflect the number of shares received in a pro rata distribution by Emergent BioSolutions, Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective on August 1, 2016.
- Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer.
- This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018.
- This report has been amended to reflect that the RSUs will vest on August 1, 2017.
- This report has been amended to reflect the 101,437 RSUs that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
- This report has been amended to include the stock options that were originally granted by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
- 49,682 of the Reporting Person's stock options are exercisable at an exercise price of \$2.47 per share; 55,586 of the Reporting Person's stock options are exercisable at an exercise price of \$2.55 per share; and 97,612 of the Reporting Person's stock options are exercisable at an exercise price \$2.97.
- 49,682 of the Reporting Person's stock options vest fully on March 10, 2017; 55,586 of the Reporting Person's stock options vest in two equal installments on March 9, 2017 and March 9, 2018; and 97,612 of the Reporting Person's stock options vest as follows: 32,538 on March 1, 2017; 32,538 on March 1, 2018 and 32,536 on March 1, 2019.
- 49,682 of the Reporting Person's stock options expire on March 10, 2021; 55,586 of the Reporting Person's stock options expire on March 9, 2022; and 97,612 expire on February 28, 2026.

/s/ Benjamin J. Stein, attorney-in-fact 09/27/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.